DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer Pharmaceutical Investing
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343 Pharmaceutical Investing
Canopy Growth and Skinvisible Sign Definitive Agreement to Bring New Products to Market Cannabis Investing News
